• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      India's Ranbaxy gets US FDA nod to manufacture, market generic of GSK's Ceftin

      Posted Atmoney.cnn.com

      BANGALORE, Feb. 6, 2008 (Thomson Financial delivered by Newstex) -- India's Ranbaxy Laboratories Ltd said its US unit has received US FDA approval to manufacture and market the generic version of GlaxoSmithKline PLC's (NYSE:GSK) paediatric anti-bacterial drug Ceftin, Cefuroxime Axetil, for oral suspension in the 125mg/5ml and 250mg/5ml dosage form.

      The pharma major said the total annual market sales for Cefuroxime Axetil Suspension were 28.7 mln usd as per IMS Health (NYSE:RX) data, December 2007.

      Jim Meehan, vice president of sales and distribution for Ranbaxy's US unit, said: 'Ranbaxy is pleased to receive this approval for Cefuroxime Axetil Suspension that now allows us to be the only generic company to offer both dosage forms for a product that is highly prescribed.'

      Copyright Thomson Financial News Limited 2007. All rights reserved.

      The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.

      February 06, 2008


       

      Share this Article!

    Back to top^